Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well vorinostat works in treating patients with relapsed
or refractory indolent non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as
vorinostat, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.